#### Edgar Filing: Nile Therapeutics, Inc. - Form 4

Nile Therapeutics, Inc. Form 4 January 29, 2008 FORM 4

Check this box

if no longer

Section 16.

Form 4 or

Form 5

1(b).

subject to

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> SCHAFER GREGORY W			2. Issuer Name <b>and</b> Ticker or Trading Symbol Nile Therapeutics, Inc. [NILT.OB]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
(Last)	(First)	(Middle) 3. Dat	e of Earliest 7	Fransaction	(-			
INC., 2850	THERAPEUTIC ) TELEGRAPH , SUITE 310	· · ·	n/Day/Year) /2008		X Director Officer (g below)		% Owner her (specify	
(Street)			4. If Amendment, Date Original			6. Individual or Joint/Group Filing(Check		
BERKELE	EY, CA 94705	Filed()	/lonth/Day/Ye	ar)		) by One Reporting F by More than One R		
(City)	(State)	(Zip) T	able I - Non-	Derivative Securities A	Acquired, Dispose	d of, or Beneficia	ally Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Code	4. Securities onAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership	

or (Instr. 3 and 4) Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

(Instr. 4)

(Instr. 4)

Following

Reported

Transaction(s)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amour
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securit

(A)

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

#### Edgar Filing: Nile Therapeutics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/	'Year)	(Instr. 3 and	4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Non-Qualified Stock Option (right to buy)	\$ 4.5	01/25/2008		А	60,000	(1)	01/25/2018	Common Stock	60,0

## **Reporting Owners**

Reporting Owner Name / Address		Relationships				
Toporting 0 m	Director	10% Owner	Officer	Other		
SCHAFER GREGO C/O NILE THERAP 2850 TELEGRAPH BERKELEY, CA 94	Х					
Signatures						
Gregory W. Schafer	01/29/2008					
<u>**</u> Signature of Reporting Person	Date					

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares subject to the option vest in three equal installments on January 25, 2009, January 25, 2010 and January 25, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.